Therapy adherence issues in Parkinson's disease

Journal of the Neurological Sciences

Volumn 289, Issue 1-2, 2010, Pages 115-118

  Grosset, Donald ^a  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

Author keywords

Adherence; Compliance; Parkinson's; Therapeutics

Indexed keywords

DOPAMINE; LEVODOPA; PRAMIPEXOLE; SELEGILINE;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; CONFUSION; DEPRESSION; DISEASE CONTROL; DOPAMINE BLOOD LEVEL; DOPAMINE DYSREGULATION SYNDROME; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TREATMENT FAILURE; DYSKINESIA; FEMALE; HUMAN; MALE; NEUROTOXICITY; PARKINSON DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SELF MEDICATION; SYNDROME; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ANALOG SCALE; VISUAL HALLUCINATION;

DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT COMPLIANCE; TIME FACTORS;

EID: 74149090933     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.08.053     Document Type: Article

References (28)

1. Viller F., Guillemin F., Briancon S., Moum T., Suurmeijer T., and van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 26 10 (1999) 2114-2122
2. Cramer J., Vachon L., Desforges C., and Sussman N.M. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 36 11 (1995) 1111-1117
3. Sackett D.L., Haynes R.B., Gibson E.S., Taylor D.W., Roberts R.S., and Johnson A.L. Patient compliance with antihypertensive regimens. Patient Couns Health Educ 1 1 (1978) 18-21
4. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 27 5 (2004) 1218-1224
5. Leopold N.A., Polansky M., and Hurka M.R. Drug adherence in Parkinson's disease. Mov Disord 19 5 (2004) 513-517
6. Grosset K.A., Bone I., and Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov Disord 20 11 (2005) 1502-1507
7. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 27 3 (1994) 202-215
8. Dutton J., Copeland L.G., Playfer J.R., and Roberts N.B. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. Clin Chem 39 4 (1993) 629-634
9. Copeland L.G., Dutton J., Roberts N.B., and Playfer J.R. Routine outpatient L-dopa monitoring in elderly patients with Parkinson's disease. Age Ageing 23 2 (1994) 138-141
10. Rudd P., Ahmed S., Zachary V., Barton C., and Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 48 6 (1990) 676-685
11. Lawrence A.D., Evans A.H., and Lees A.J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. Lancet Neurol 2 10 (2003) 595-604
12. Rascol O., Brooks D.J., Brunt E.R., Korczyn A.D., Poewe W.H., and Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 13 1 (1998) 39-45
13. The Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 278 2 (1997) 125-130
14. Hughes D.A., Bagust A., Haycox A., and Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 19 12 (2001) 1185-1197
15. Stephenson B.J., Rowe B.H., Haynes R.B., Macharia W.M., and Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed?. JAMA 269 21 (1993) 2779-2781
16. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., and Ouellette V.L. How often is medication taken as prescribed? A novel assessment technique. JAMA 261 22 (1989) 3273-3277
17. Rand C.S., Wise R.A., Nides M., Simmons M.S., Bleecker E.R., Kusek J.W., et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 146 6 (1992) 1559-1564
18. Grosset K.A., Bone I., Reid J.L., and Grosset D. Measuring therapy adherence in Parkinson's disease: a comparison of methods. J Neurol Neurosurg Psychiatry 77 2 (2006) 249-251
19. Grosset D.G., Antonini A., Canesi M., Pezzoli G., Lees A., Shaw K., Cubo E., Martinez-Martin P., Rascol O., Negres-Pages L., Senard A., Schwarz J., Strecker K., Reichmann H., Storch A., Lohle M., Stocchi F., and Grosset K.A. Adherence to antiparkinson medication in a multi-centre European study. Mov Disord. 24 6 (2009) 826-832
20. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 8 (2001) 1296-1310
21. Ciechanowski P.S., Katon W.J., and Russo J.E. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 160 21 (2000) 3278-3285
22. DiMatteo M.R., Lepper H.S., and Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160 14 (2000) 2101-2107
23. Newman E.J., Grosset D.G., and Kennedy P.G. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care (2008)
24. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25 5 (1989) 473-478
25. Pearce R.K., Banerji T., Jenner P., and Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13 2 (1998) 234-241
26. Gagnon C., Bedard P.J., and Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 178 1 (1990) 115-120
27. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 20 (2000) 1484-1491
28. The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284 15 (2000) 1931-1938